Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1828
Peer-review started: January 21, 2019
First decision: February13, 2019
Revised: February 21, 2019
Accepted: March 1, 2019
Article in press: March 2, 2019
Published online: April 21, 2019
To study whether lysyl oxidase (LOX) and hypoxia-inducible factor 1α (HIF1α) can be used as prognostic and predictive biomarkers in gastric cancer (GC).
To provide the prognostic and predictive biomarkers for treating GC.
To explore the interaction between cancer and factors in the metabolic microenvironment and determine predictive biomarkers of GC.
Patients and samples: This work is difficult and requires patient approval.
RNA extraction and cDNA synthesis: This work requires a lot of time, and so the manipulator should be patient. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR): The manipulator should add the samples accurately during qRT-PCR analysis. Immunohistochemistry: The experiments take a long time, and the manipulator should perform the experiments step by step. Statistical analysis: All of the experiments were repeated at least three times, and the statistical analysis was then performed.
The expression levels of LOX and HIF1α increased in the tumor tissues and blood samples of patients with GC. The expression levels of LOX and HIF1α were related to the clinicopathological characteristics and prognosis of GC.
LOX and HIF1α can be used as prognostic and predictive biomarkers for the treatment of GC. Our study indicated that the expression of LOX and HIF1α was upregulated in patients with GC compared with the control group. In addition, the expression of LOX and HIF1α was related to the clinicopathological characteristics and prognosis of GC.
The present study suggested that LOX and HIF1α might be used as both prognostic and predictive biomarkers for GC, and provided a link between LOX, HIF1α and GC.